MacroGenics Inc (NASDAQ:MGNX) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,650,000 shares, a growth of 7.0% from the December 15th total of 3,410,000 shares. Based on an average daily volume of 557,900 shares, the short-interest ratio is presently 6.5 days. Approximately 8.3% of the company’s shares are short sold.

Several equities analysts recently commented on the stock. BidaskClub upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Friday, December 20th. Zacks Investment Research upgraded shares of MacroGenics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Thursday, January 9th. Leerink Swann cut their price target on shares of MacroGenics from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Guggenheim assumed coverage on shares of MacroGenics in a report on Wednesday, November 20th. They set a “hold” rating on the stock. Finally, Wedbush cut their price target on shares of MacroGenics from $23.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.83.

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace North America L.P. purchased a new stake in MacroGenics in the 1st quarter valued at about $59,000. Marshall Wace LLP purchased a new stake in MacroGenics in the 1st quarter valued at about $80,000. Tower Research Capital LLC TRC purchased a new stake in MacroGenics in the 3rd quarter valued at about $94,000. Metropolitan Life Insurance Co NY lifted its position in shares of MacroGenics by 23.4% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 16,259 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 3,081 shares during the period. Finally, Stifel Financial Corp lifted its position in shares of MacroGenics by 4.9% in the 3rd quarter. Stifel Financial Corp now owns 20,287 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 950 shares during the period. 94.92% of the stock is owned by institutional investors.

MacroGenics stock traded down $0.18 during trading hours on Wednesday, hitting $11.72. The company had a trading volume of 459,815 shares, compared to its average volume of 585,637. The firm has a market cap of $541.48 million, a P/E ratio of -2.80 and a beta of 2.31. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.79 and a current ratio of 4.79. MacroGenics has a 1 year low of $7.43 and a 1 year high of $32.32. The company has a 50-day moving average price of $10.42 and a two-hundred day moving average price of $12.18.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.03. The company had revenue of $18.74 million during the quarter, compared to analysts’ expectations of $23.33 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. As a group, equities research analysts anticipate that MacroGenics will post -3.4 EPS for the current year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Story: P/E Growth (PEG)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.